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Between June 1996 and December 1997 immunological reconstitution was analyzed in 27 consecutive adult patients (pts.) autografted at our institution with either unselected PBϮBM stem cells (group I, n=16) or CD34+-immunoselected (Cellpro) PB (group II, n=11) obtained after mobilization with high-dose chemotherapy + G-CSF. Pts. were re-infused with either 5.3 (0. 85-11.35 30, 60, 90, 180 and 360 days after SCT using quantitative and functional parameters. Whereas leukocyte engraftment was significantly faster in pts. autografted with CD34+-enriched stem cells (13 vs 19 days, p=0.0074) there were no significant differences between the two groups with respect to T-and B-lymphocyte reconstitution. In both groups the percentage of CD3+ cells returned to baseline values within 60 days after transplantation. Although CD4 counts were lower in the CD34-enriched group the differences did not reach statistical significance. Restoration of B lymphocytes needed up to three months in both groups but was not accompanied by significant alterations of serum immunoglobulin levels probably due to the biweekly administration of IVIG. Monocytes were significantly increased only until day +30 after SCT whereas NK cells were increased for up to 90 days without a significant difference between the two study groups. In contrast to the rapid quantitative reconstitution functional parameters (MLC response, PHA-, and ConA stimulation) were impaired for up to six months after SCT in both groups. In conclusion, in adults immune reconstitution after autografting with immunoselected CD34+ cells was not delayed as compared to unselected BMϮPBSCT. Moreover, the velocity of restoration of quantitative and qualitative immune parameters after CD34+-enriched APBSCT was not correlated to the absolute CD34+ cell number transfused although from the clinical point of view pts. autografted with a low CD34+ cell number had prolonged infectious disease problems within the first year after SCT. To date controversy exists about reliable predictors of sustained platelet reconstitution after autologous peripheral blood or bone marrow rescue with high dose chemoradiotherapy. To determine the relative importance of selected variables we collated data on CD34+ cells infused, CFU-GM, CFU-GEMM, CFU-Meg and LTC-IC activity, previous chemotherapy and mobilisation regimens in a cohort of 35 patients. Patients had NHL/Hodgkins:18, myeloma:9, AML:3, BCLL:2, CML:1, testicular Ca:1 and breast Ca:1. Myeloablative chemotherapy consisted of BEAM for lymphoma, melphalan 200mg/m 2 for myeloma, Bu/Cy for AML and Cy/TBI for CLL patients. Sustained platelet engraftment was defined as transfusion independent counts of Ͼ20 and Ͼ50×10 9/L. Platelet recovery to 20 and 50×10 9/L ranged from 9 to Ͼ320 and 13 to Ͼ320 days respectively. No statistical correlation was noted with mobilisation regimes or previous chemotherapy although 3 patients with significant platelet engraftment problems were particularly heavily pre-treated. The best correlates with adequate sustained platelet recovery in PBSCT patients (32/35) were number of CD34+ cells infused, CFU-GEMM Ͼ1×10 5/kg and the presence of LTC-IC activity. As only 1% or less of all CD34+ cells are primitive haemopoietic stem cells with long term reconstitution potential the apparent correlation between sustained platelet engraftment and total CD34 numbers (but not CFU-Megs) infused implies that there may be other important cell types involved.
